Report top-line results from the Phase 3 LAVENDER study

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 8 Nov 2021
Due: 31 Dec 2021
Delivered: December 2021

Deadline
Met
Late
Not met
Today

What the company said

“Top-line results from the Phase 3 LAVENDER study evaluating trofinetide for the treatment of Rett syndrome are expected in the fourth quarter of 2021.”

SourceAcadia Pharmaceuticals Inc. Form 8-K press release, 2021-11-08
FilingSEC filing index
Deadline as statedin the fourth quarter of 2021
Deadline used31 Dec 2021, the last day of the stated period
TypeProduct
Permanent referenceKI-C-2021-ACAD-002570
Cite as https://keptindex.org/c/KI-C-2021-ACAD-002570/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company announced positive top-line results from the Phase 3 LAVENDER study in December 2021, meeting the commitment to report these results within the fourth quarter of 2021.

A
Acadia Pharmaceuticals Inc. 10-K filed 2022-03-01 Regulatory filing · published 1 Mar 2022 · retrieved 1 Oct 2026 · kept permanently by the SEC · fingerprint 1169afac1c16
“In December 2021, we announced positive top-line results from the pivotal Phase 3 LAVENDER study of trofinetide in Rett Syndrome.” ✓ confirmed on the page

Market reaction: the shares moved -3.9% against the S&P 500 over the three sessions around the disclosure (28 Feb 2022 to 3 Mar 2022). What this measures

Checked 1 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Deadline drift +1765 days
2 versions

Version 1 · original · stated 8 Nov 2021

Deadline 31 Dec 2021 (“in the fourth quarter of 2021”) · wording expected
Version 2 · stated 8 May 2023

Deadline 31 Mar 2024 (“early 2024”) · wording expected

“with top-line results expected in early 2024.”
Source for this version
Version 3 · stated 25 Feb 2026

Deadline 31 Oct 2026 (“August to October 2026”) · wording firm

“Phase 2 top-line results readout from the remlifanserin Alzheimer’s disease psychosis study remains on track for August to October 2026 timeframe”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout late
Indicative materiality: High rules
Action: Report
Deliverable: Phase 3 LAVENDER study top-line results
Language: Expected (“expects”, “plans”)
In the company’s control: High
Specificity: High

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Acadia Pharmaceuticals Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.